Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 218

1.

Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non-small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial.

Reck M, Schenker M, Lee KH, Provencio M, Nishio M, Lesniewski-Kmak K, Sangha R, Ahmed S, Raimbourg J, Feeney K, Corre R, Franke FA, Richardet E, Penrod JR, Yuan Y, Nathan FE, Bhagavatheeswaran P, DeRosa M, Taylor F, Lawrance R, Brahmer J.

Eur J Cancer. 2019 Jun 10;116:137-147. doi: 10.1016/j.ejca.2019.05.008. [Epub ahead of print]

2.

Multidisciplinary consensus statement on the clinical management of patients with stage III non-small cell lung cancer.

Majem M, Hernández-Hernández J, Hernando-Trancho F, Rodríguez de Dios N, Sotoca A, Trujillo-Reyes JC, Vollmer I, Delgado-Bolton R, Provencio M.

Clin Transl Oncol. 2019 Jun 6. doi: 10.1007/s12094-019-02134-7. [Epub ahead of print]

PMID:
31172444
3.

Healthcare resource utilization and associated cost analysis of the PROCLAIM study in patients with stage III non-small cell lung cancer.

Govindan R, Senan S, Dickgreber N, Provencio M, Wu YL, Syrigos K, Parente B, Wilson M, Ziemiecki R, Chouaki N, Hossain A, San Antonio B, Winfree K, Vokes EE.

Curr Med Res Opin. 2019 May 24:1. doi: 10.1080/03007995.2019.1623185. [Epub ahead of print]

PMID:
31125266
4.

Nivolumab for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma: Safety and Efficacy in the Phase II CheckMate 205 Study.

Ramchandren R, Domingo-Domènech E, Rueda A, Trněný M, Feldman TA, Lee HJ, Provencio M, Sillaber C, Cohen JB, Savage KJ, Willenbacher W, Ligon AH, Ouyang J, Redd R, Rodig SJ, Shipp MA, Sacchi M, Sumbul A, Armand P, Ansell SM.

J Clin Oncol. 2019 May 21:JCO1900315. doi: 10.1200/JCO.19.00315. [Epub ahead of print]

PMID:
31112476
5.

Genetic Variants Associated with Cancer Therapy-Induced Cardiomyopathy.

Garcia-Pavia P, Kim Y, Alejandra Restrepo-Cordoba M, Lunde IG, Wakimoto H, Smith AM, Toepfer CN, Getz K, Gorham J, Patel P, Ito K, Willcox JA, Arany Z, Li J, Owens AT, Govind R, Nuñez B, Mazaika E, Bayes-Genis A, Walsh R, Finkelman B, Lupon J, Whiffin N, Serrano I, Midwinter W, Wilk A, Bardaji A, Ingold N, Buchan R, Tayal U, Pascual-Figal DA, de Marvao A, Ahmad M, Garcia-Pinilla JM, Pantazis A, Dominguez F, Baksi AJ, O'Regan DP, Rosen SD, Prasad SK, Lara-Pezzi E, Provencio M, Lyon AR, Alonso-Pulpon L, Cook SA, DePalma SR, Barton PJR, Aplenc R, Seidman JG, Ky B, Ware JS, Seidman CE.

Circulation. 2019 Apr 16. doi: 10.1161/CIRCULATIONAHA.118.037934. [Epub ahead of print]

PMID:
30987448
6.

Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial.

Michels S, Massutí B, Schildhaus HU, Franklin J, Sebastian M, Felip E, Grohé C, Rodriguez-Abreu D, Abdulla DSY, Bischoff H, Brandts C, Carcereny E, Corral J, Dingemans AC, Pereira E, Fassunke J, Fischer RN, Gardizi M, Heukamp L, Insa A, Kron A, Menon R, Persigehl T, Reck M, Riedel R, Rothschild SI, Scheel AH, Scheffler M, Schmalz P, Smit EF, Limburg M, Provencio M, Karachaliou N, Merkelbach-Bruse S, Hellmich M, Nogova L, Büttner R, Rosell R, Wolf J.

J Thorac Oncol. 2019 Apr 9. pii: S1556-0864(19)30276-X. doi: 10.1016/j.jtho.2019.03.020. [Epub ahead of print]

PMID:
30978502
7.

Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer.

Sequist LV, Gray JE, Harb WA, Lopez-Chavez A, Doebele RC, Modiano MR, Jackman DM, Baggstrom MQ, Atmaca A, Felip E, Provencio M, Cobo M, Adiwijaya B, Kuesters G, Kamoun WS, Andreas K, Pipas JM, Santillana S, Cho BC, Park K, Shepherd FA.

Oncologist. 2019 Apr 11. pii: theoncologist.2018-0695. doi: 10.1634/theoncologist.2018-0695. [Epub ahead of print]

PMID:
30975923
8.

Lung cancer and residential radon in never-smokers: A pooling study in the Northwest of Spain.

Lorenzo-González M, Ruano-Ravina A, Torres-Durán M, Kelsey KT, Provencio M, Parente-Lamelas I, Leiro-Fernández V, Vidal-García I, Castro-Añón O, Martínez C, Golpe-Gómez A, Zapata-Cachafeiro M, Piñeiro-Lamas M, Pérez-Ríos M, Abal-Arca J, Montero-Martínez C, Fernández-Villar A, Barros-Dios JM.

Environ Res. 2019 May;172:713-718. doi: 10.1016/j.envres.2019.03.011. Epub 2019 Mar 6.

PMID:
30903971
9.

Consensus on the use of immune-related response criteria to evaluate the efficacy of immunotherapy in non-small cell lung cancer.

Provencio M, Carcereny E, Artal Á.

Clin Transl Oncol. 2019 Mar 22. doi: 10.1007/s12094-019-02072-4. [Epub ahead of print]

PMID:
30903517
10.

Cisplatin resistance involves a metabolic reprogramming through ROS and PGC-1α in NSCLC which can be overcome by OXPHOS inhibition.

Cruz-Bermúdez A, Laza-Briviesca R, Vicente-Blanco RJ, García-Grande A, Coronado MJ, Laine-Menéndez S, Palacios-Zambrano S, Moreno-Villa MR, Ruiz-Valdepeñas AM, Lendinez C, Romero A, Franco F, Calvo V, Alfaro C, Acosta PM, Salas C, Garcia JM, Provencio M.

Free Radic Biol Med. 2019 May 1;135:167-181. doi: 10.1016/j.freeradbiomed.2019.03.009. Epub 2019 Mar 14.

11.

Applying Data Science methods and tools to unveil healthcare use of lung cancer patients in a teaching hospital in Spain.

Cruz-Bermúdez JL, Parejo C, Martínez-Ruíz F, Sánchez-González JC, Ramos Martín-Vegue A, Royuela A, Rodríguez-González A, Menasalvas-Ruiz E, Provencio M.

Clin Transl Oncol. 2019 Mar 12. doi: 10.1007/s12094-019-02074-2. [Epub ahead of print]

PMID:
30864021
12.

Genomic analyses of microdissected Hodgkin and Reed-Sternberg cells: mutations in epigenetic regulators and p53 are frequent in refractory classic Hodgkin lymphoma.

Mata E, Fernández S, Astudillo A, Fernández R, García-Cosío M, Sánchez-Beato M, Provencio M, Estévez M, Montalbán C, Piris MA, García JF.

Blood Cancer J. 2019 Mar 11;9(3):34. doi: 10.1038/s41408-019-0195-7. No abstract available.

13.

Transformed follicular lymphoma in the rituximab era: A report from the Spanish Lymphoma Oncology Group.

Méndez M, Torrente M, Sánchez-Beato M, González-Rincón J, Royuela A, Gómez-Codina J, de la Cruz-Merino L, Rueda A, Llanos M, Quero C, Rodríguez-Abreu D, Gumá J, Monsalvo S, Sabin P, Provencio M.

Hematol Oncol. 2019 Apr;37(2):143-150. doi: 10.1002/hon.2601. Epub 2019 Apr 4.

PMID:
30840776
14.

Unraveling transformation of follicular lymphoma to diffuse large B-cell lymphoma.

González-Rincón J, Méndez M, Gómez S, García JF, Martín P, Bellas C, Pedrosa L, Rodríguez-Pinilla SM, Camacho FI, Quero C, Pérez-Callejo D, Rueda A, Llanos M, Gómez-Codina J, Piris MA, Montes-Moreno S, Bárcena C, Rodríguez-Abreu D, Menárguez J, de la Cruz-Merino L, Monsalvo S, Parejo C, Royuela A, Kwee I, Cascione L, Arribas A, Bertoni F, Mollejo M, Provencio M, Sánchez-Beato M.

PLoS One. 2019 Feb 25;14(2):e0212813. doi: 10.1371/journal.pone.0212813. eCollection 2019.

15.

Nivolumab-associated digital small-vessel vasculitis in a patient with an advanced renal cell carcinoma.

Franco F, Méndez M, Gutierrez L, Sanz J, Calvo V, Provencio M.

Immunotherapy. 2019 Apr;11(5):379-384. doi: 10.2217/imt-2018-0082.

PMID:
30786844
16.

Treatment of induction in resectable NSCLC with chemotherapy, followed by surgery and erlotinib.

Franco F, Provencio M.

Ann Transl Med. 2018 Nov;6(Suppl 1):S31. doi: 10.21037/atm.2018.09.38. No abstract available.

17.

Clinical utility of plasma-based digital next-generation sequencing in patients with advance-stage lung adenocarcinomas with insufficient tumor samples for tissue genotyping.

Zugazagoitia J, Ramos I, Trigo JM, Palka M, Gómez-Rueda A, Jantus-Lewintre E, Camps C, Isla D, Iranzo P, Ponce-Aix S, García-Campelo R, Provencio M, Franco F, Bernabé R, Juan-Vidal O, Felip E, de Castro J, Sanchez-Torres JM, Faul I, Lanman RB, Garrido P, Paz-Ares L.

Ann Oncol. 2019 Feb 1;30(2):290-296. doi: 10.1093/annonc/mdy512.

PMID:
30535340
18.

Efficacy of the combination of rituximab-bendamustine as a second-line treatment in patients with follicular lymphoma who progress after immunochemotherapy: a phase II trial of the Spanish Lymphoma Oncology Group.

Rueda A, Calvo V, Casanova M, Rodriguez-Abreu D, Aguiar D, Llanos M, Alvarez R, Martinez-Banaclocha N, Alfaro J, Quero C, Blasco A, de la Cruz Merino L, Herrero J, García-Arroyo FR, Provencio M.

Leuk Lymphoma. 2019 Jun;60(6):1576-1579. doi: 10.1080/10428194.2018.1542147. Epub 2018 Dec 5. No abstract available.

PMID:
30516082
19.

Association of PALB2 Messenger RNA Expression with Platinum-Docetaxel Efficacy in Advanced Non-Small Cell Lung Cancer.

Karachaliou N, Bracht JWP, Fernandez Bruno M, Drozdowskyj A, Gimenez Capitan A, Moran T, Carcereny E, Cobo M, Domine M, Chaib I, Ramirez JL, Camps C, Provencio M, Vergnenegre A, Lopez-Vivanco G, Majem M, Massuti B, Rosell R.

J Thorac Oncol. 2019 Feb;14(2):304-310. doi: 10.1016/j.jtho.2018.10.168. Epub 2018 Nov 22.

PMID:
30472259
20.

SEOM clinical guidelines for the treatment of non-small cell lung cancer (2018).

Majem M, Juan O, Insa A, Reguart N, Trigo JM, Carcereny E, García-Campelo R, García Y, Guirado M, Provencio M.

Clin Transl Oncol. 2019 Jan;21(1):3-17. doi: 10.1007/s12094-018-1978-1. Epub 2018 Nov 17.

21.

Peritoneal washing is an adequate source for somatic BRCA1/2 mutation testing in ovarian malignancies.

Barquín M, Maximiano C, Pérez-Barrios C, Sanchez-Herrero E, Soriano M, Colmena M, García-Espantaleón M, Tejerina González E, Gutierrez L, Sánchez Ruiz AC, Torrente M, Provencio M, Romero A.

Pathol Res Pract. 2019 Feb;215(2):392-394. doi: 10.1016/j.prp.2018.10.028. Epub 2018 Oct 28.

PMID:
30392916
22.

Cancer-associated fibroblasts modify lung cancer metabolism involving ROS and TGF-β signaling.

Cruz-Bermúdez A, Laza-Briviesca R, Vicente-Blanco RJ, García-Grande A, Coronado MJ, Laine-Menéndez S, Alfaro C, Sanchez JC, Franco F, Calvo V, Romero A, Martin-Acosta P, Salas C, Garcia JM, Provencio M.

Free Radic Biol Med. 2019 Jan;130:163-173. doi: 10.1016/j.freeradbiomed.2018.10.450. Epub 2018 Nov 1.

23.

Using the Lymph2Cx assay for assessing cell-of-origin subtypes of HIV-related diffuse large B-cell lymphoma.

Baptista MJ, Tapia G, Morgades M, Muncunill J, Muñoz-Marmol AM, Montoto S, Gribben JG, Calaminici M, Martinez A, Gonzalez-Farre B, Dlouhy I, González-Barca E, Terol MJ, Miralles P, Alcoceba M, Vall-Llovera F, Briones J, Abrisqueta P, Abella E, Provencio M, García-Ballesteros C, Moraleda JM, Sancho JM, Ribera JM, Mate JL, Navarro JT.

Leuk Lymphoma. 2019 Apr;60(4):1087-1091. doi: 10.1080/10428194.2018.1512711. Epub 2018 Oct 15. No abstract available.

PMID:
30322315
24.

A combination of hydroxytyrosol, omega-3 fatty acids and curcumin improves pain and inflammation among early stage breast cancer patients receiving adjuvant hormonal therapy: results of a pilot study.

Martínez N, Herrera M, Frías L, Provencio M, Pérez-Carrión R, Díaz V, Morse M, Crespo MC.

Clin Transl Oncol. 2019 Apr;21(4):489-498. doi: 10.1007/s12094-018-1950-0. Epub 2018 Oct 6.

PMID:
30293230
25.

Lung cancer in Spanish women: The WORLD07 project.

Garrido P, Viñolas N, Isla D, Provencio M, Majem M, Artal A, Carcereny E, Garcia Campelo R, Lianes P, De La Peñas R, Felip E.

Eur J Cancer Care (Engl). 2019 Jan;28(1):e12941. doi: 10.1111/ecc.12941. Epub 2018 Oct 2.

PMID:
30277293
26.

Consolidation treatment with yttrium-90 ibritumomab tiuxetan after new induction regimen in advanced stage follicular lymphoma: update results from the Spanish Lymphoma Oncology Group trial after a median follow-up of 8.5-years.

Provencio M, Franco F, Gómez-Codina J, Quero Blanco C, Llanos M, Garcia-Arroyo F, de la Cruz L, Gumá J, Delgado JR, Álvarez R, Chacón JI, Royuela A, Rueda A.

Leuk Lymphoma. 2019 Mar;60(3):856-859. doi: 10.1080/10428194.2018.1509322. Epub 2018 Sep 20. No abstract available.

PMID:
30234403
27.

Abemaciclib in Combination with Single-Agent Options in Patients with Stage IV Non-Small Cell Lung Cancer: A Phase Ib Study.

Kim ES, Kelly K, Paz-Ares LG, Garrido P, Jalal S, Mahadevan D, Gutierrez M, Provencio M, Schaefer E, Shaheen M, Johnston EL, Turner PK, Kambhampati SRP, Beckmann R, Hossain A, John WJ, Goldman JW.

Clin Cancer Res. 2018 Nov 15;24(22):5543-5551. doi: 10.1158/1078-0432.CCR-18-0651. Epub 2018 Aug 6.

PMID:
30082474
28.

Hyperprogression as a distinct outcome after immunotherapy.

Fuentes-Antrás J, Provencio M, Díaz-Rubio E.

Cancer Treat Rev. 2018 Nov;70:16-21. doi: 10.1016/j.ctrv.2018.07.006. Epub 2018 Jul 18. Review.

PMID:
30053725
29.

Profiling Lung Cancer Patients Using Electronic Health Records.

Menasalvas Ruiz E, Tuñas JM, Bermejo G, Gonzalo Martín C, Rodríguez-González A, Zanin M, González de Pedro C, Méndez M, Zaretskaia O, Rey J, Parejo C, Cruz Bermudez JL, Provencio M.

J Med Syst. 2018 May 31;42(7):126. doi: 10.1007/s10916-018-0975-9.

PMID:
29855732
30.

An exploratory, large-scale study of pain and quality of life outcomes in cancer patients with moderate or severe pain, and variables predicting improvement.

Maximiano C, López I, Martín C, Zugazabeitia L, Martí-Ciriquián JL, Núñez MA, Contreras J, Herdman M, Traseira S, Provencio M.

PLoS One. 2018 Apr 3;13(4):e0193233. doi: 10.1371/journal.pone.0193233. eCollection 2018.

31.

Description and Survival of Stage I and II Lung Cancer Patients.

Pérez-Martínez O, Vidal-García I, Montero-Martínez C, Provencio M, Ruano-Ravina A.

Arch Bronconeumol. 2018 Aug;54(8):420-426. doi: 10.1016/j.arbres.2018.02.007. Epub 2018 Mar 16. English, Spanish.

32.

Long-term follow up of Hodgkin lymphoma.

Perez-Callejo D, Zurutuza L, Royuela A, Torrente M, Núñez B, Calvo V, Méndez M, Franco F, Brenes MA, Sánchez JC, Provencio M.

Oncotarget. 2018 Feb 3;9(14):11638-11645. doi: 10.18632/oncotarget.24392. eCollection 2018 Feb 20.

33.

Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma.

Jurczak W, Zinzani PL, Gaidano G, Goy A, Provencio M, Nagy Z, Robak T, Maddocks K, Buske C, Ambarkhane S, Winderlich M, Dirnberger-Hertweck M, Korolkiewicz R, Blum KA.

Ann Oncol. 2018 May 1;29(5):1266-1272. doi: 10.1093/annonc/mdy056.

34.

Prognostic value of quantitative ctDNA levels in non small cell lung cancer patients.

Provencio M, Torrente M, Calvo V, Pérez-Callejo D, Gutiérrez L, Franco F, Pérez-Barrios C, Barquín M, Royuela A, García-García F, Bueno C, Garcia-Grande A, Camps C, Massuti B, Sotomayor E, Romero A.

Oncotarget. 2017 Nov 16;9(1):488-494. doi: 10.18632/oncotarget.22470. eCollection 2018 Jan 2.

35.

Clinical management and outcome of patients with advanced NSCLC carrying EGFR mutations in Spain.

Arriola E, García Gómez R, Diz P, Majem M, Martínez Aguillo M, Valdivia J, Paredes A, Sánchez-Torres JM, Peralta Muñoz S, Barneto I, Gutierrez V, Andrade Santiago JM, Aparisi F, Isla D, Ponce S, Vicente Baz D, Artal A, Amador M, Provencio M.

BMC Cancer. 2018 Jan 30;18(1):106. doi: 10.1186/s12885-018-4004-7.

36.

Analysis of the mutational landscape of classic Hodgkin lymphoma identifies disease heterogeneity and potential therapeutic targets.

Mata E, Díaz-López A, Martín-Moreno AM, Sánchez-Beato M, Varela I, Mestre MJ, Santonja C, Burgos F, Menárguez J, Estévez M, Provencio M, Sánchez-Espiridión B, Díaz E, Montalbán C, Piris MA, García JF.

Oncotarget. 2017 Nov 30;8(67):111386-111395. doi: 10.18632/oncotarget.22799. eCollection 2017 Dec 19.

37.

Mutational profile of primary breast diffuse large B-cell lymphoma.

Franco F, González-Rincón J, Lavernia J, García JF, Martín P, Bellas C, Piris MA, Pedrosa L, Miramón J, Gómez-Codina J, Rodríguez-Abreu D, Machado I, Illueca C, Alfaro J, Provencio M, Sánchez-Beato M.

Oncotarget. 2017 Oct 24;8(61):102888-102897. doi: 10.18632/oncotarget.21986. eCollection 2017 Nov 28.

38.

Twice-daily chemoradiotherapy must still be the choice for patients with limited-stage small-cell lung cancer.

Franco F, Pérez-Callejo D, Provencio M.

J Thorac Dis. 2017 Sep;9(9):2843-2846. doi: 10.21037/jtd.2017.08.113. No abstract available.

39.

PGC-1alpha levels correlate with survival in patients with stage III NSCLC and may define a new biomarker to metabolism-targeted therapy.

Cruz-Bermúdez A, Vicente-Blanco RJ, Laza-Briviesca R, García-Grande A, Laine-Menéndez S, Gutiérrez L, Calvo V, Romero A, Martín-Acosta P, García JM, Provencio M.

Sci Rep. 2017 Nov 30;7(1):16661. doi: 10.1038/s41598-017-17009-6.

40.

Genotype-based selection of treatment of patients with advanced colorectal cancer (SETICC): a pharmacogenetic-based randomized phase II trial.

Abad A, Martínez-Balibrea E, Viéitez JM, Alonso-Orduña V, García Alfonso P, Manzano JL, Massutí B, Benavides M, Carrato A, Zanui M, Gallego J, Grávalos C, Conde V, Provencio M, Valladares-Ayerbes M, Salazar R, Sastre J, Montagut C, Rivera F, Aranda E.

Ann Oncol. 2018 Feb 1;29(2):439-444. doi: 10.1093/annonc/mdx737.

PMID:
29145602
41.

Alcohol consumption and lung cancer risk in never smokers: a pooled analysis of case-control studies.

García Lavandeira JA, Ruano-Ravina A, Kelsey KT, Torres-Durán M, Parente-Lamelas I, Leiro-Fernández V, Zapata M, Abal-Arca J, Vidal-García I, Montero-Martínez C, Amenedo M, Castro-Añón O, Golpe-Gómez A, Guzmán-Taveras R, Martínez C, Provencio M, Mejuto-Martí MJ, García-García S, Fernández-Villar A, Piñeiro M, Barros-Dios JM.

Eur J Public Health. 2018 Jun 1;28(3):521-527. doi: 10.1093/eurpub/ckx196.

PMID:
29140412
42.

Environmental tobacco smoke exposure and EGFR and ALK alterations in never smokers' lung cancer. Results from the LCRINS study.

Torres-Durán M, Ruano-Ravina A, Kelsey KT, Parente-Lamelas I, Leiro-Fernández V, Abdulkader I, Provencio M, Abal-Arca J, Castro-Añón O, Montero-Martínez C, Vidal-García I, Amenedo M, Golpe-Gómez A, Martínez C, Guzmán-Taveras R, Mejuto-Martí MJ, Fernández-Villar A, Barros-Dios JM.

Cancer Lett. 2017 Dec 28;411:130-135. doi: 10.1016/j.canlet.2017.09.042. Epub 2017 Oct 5.

PMID:
28987389
43.

Dynamic circulating tumor DNA quantificaton for the individualization of non-small-cell lung cancer patients treatment.

Provencio M, Torrente M, Calvo V, Gutiérrez L, Pérez-Callejo D, Pérez-Barrios C, Barquín M, Royuela A, Rodriguez-Alfonso B, Sotelo M, Cruz-Bermúdez JL, Mendez M, Cruz-Bermúdez A, Romero A.

Oncotarget. 2017 Aug 7;8(36):60291-60298. doi: 10.18632/oncotarget.20016. eCollection 2017 Sep 1.

44.

Concordance between circulating tumor cells and clinical status during follow-up in anaplastic lymphoma kinase (ALK) non-small-cell lung cancer patients.

Provencio M, Pérez-Callejo D, Torrente M, Martin P, Calvo V, Gutiérrez L, Franco F, Coronado MJ, Cruz-Bermúdez JL, Ruiz-Valdepeñas AM, Cruz-Bermúdez A, Sánchez-Beato M, Romero A, García-Grande A.

Oncotarget. 2017 Jul 31;8(35):59408-59416. doi: 10.18632/oncotarget.19722. eCollection 2017 Aug 29.

45.

mRNA in exosomas as a liquid biopsy in non-Hodgkin Lymphoma: a multicentric study by the Spanish Lymphoma Oncology Group.

Provencio M, Rodríguez M, Cantos B, Sabín P, Quero C, García-Arroyo FR, Rueda A, Maximiano C, Rodríguez-Abreu D, Sánchez A, Silva J, García V.

Oncotarget. 2017 Mar 22;8(31):50949-50957. doi: 10.18632/oncotarget.16435. eCollection 2017 Aug 1.

46.

Lung cancer as a cardiotoxic state: a review.

Pérez-Callejo D, Torrente M, Brenes MA, Núñez B, Provencio M.

Med Oncol. 2017 Aug 9;34(9):159. doi: 10.1007/s12032-017-1012-4. Review.

PMID:
28795306
47.

Lung cancer in lung transplantation: incidence and outcome.

Pérez-Callejo D, Torrente M, Parejo C, Laporta R, Ussetti P, Provencio M.

Postgrad Med J. 2018 Jan;94(1107):15-19. doi: 10.1136/postgradmedj-2017-134868. Epub 2017 Aug 4.

PMID:
28778949
48.

Exercise and the Hallmarks of Cancer.

Ruiz-Casado A, Martín-Ruiz A, Pérez LM, Provencio M, Fiuza-Luces C, Lucia A.

Trends Cancer. 2017 Jun;3(6):423-441. doi: 10.1016/j.trecan.2017.04.007. Epub 2017 Jun 3. Review.

PMID:
28718417
49.

Efficacy of tyrosine kinase inhibitors in EGFR-mutant lung cancer women in a real-world setting: the WORLD07 database.

Remon J, Isla D, Garrido P, de Castro J, Majem M, Viñolas N, Artal A, Carcereny E, García-Campelo MR, Lianes P, Provencio M, Juan O, Diz P, Blanco R, Lopez-Castro R, Maestu I, Vadell C, Felip E.

Clin Transl Oncol. 2017 Dec;19(12):1537-1542. doi: 10.1007/s12094-017-1700-8. Epub 2017 Jun 28.

PMID:
28660482
50.

A phase Ib trial of continuous once-daily oral afatinib plus sirolimus in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer and/or disease progression following prior erlotinib or gefitinib.

Moran T, Palmero R, Provencio M, Insa A, Majem M, Reguart N, Bosch-Barrera J, Isla D, Costa EC, Lee C, Puig M, Kraemer S, Schnell D, Rosell R.

Lung Cancer. 2017 Jun;108:154-160. doi: 10.1016/j.lungcan.2017.03.009. Epub 2017 Mar 22.

PMID:
28625629

Supplemental Content

Loading ...
Support Center